Literature DB >> 1817041

Norrbottnian type of Gaucher disease--clinical, biochemical and molecular biology aspects: successful treatment with bone marrow transplantation.

L Svennerholm1, A Erikson, C G Groth, O Ringdén, J E Månsson.   

Abstract

The Norrbottnian type of Gaucher disease is a well defined nosological entity with a characteristic course and clinical manifestations. The disease is caused by a deficiency of the enzyme glucosylceramidase (cerebroside-beta-glucosidase). Studies of genomic DNA and cDNA encoding the enzyme show a single base substitution in exon 10 in the Norrbottnian patients. The enzymic lesion causes an accumulation of glucosylceramide and glucosylsphingosine in cells of the monocyte-macrophage system, particularly in spleen, liver and bone marrow. Early splenectomy results in severe symptoms from skeleton and CNS, owing to accelerated storage of glucosylceramide in these organs. Bone marrow transplantation had a life-saving effect and seems to be the method of choice for beneficial enzyme replacement therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1817041     DOI: 10.1159/000112184

Source DB:  PubMed          Journal:  Dev Neurosci        ISSN: 0378-5866            Impact factor:   2.984


  7 in total

Review 1.  Lysosphingolipids and sphingolipidoses: Psychosine in Krabbe's disease.

Authors:  Stefka Spassieva; Erhard Bieberich
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 2.  Gaucher disease as a paradigm of current issues regarding single gene mutations of humans.

Authors:  E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

Review 3.  Hematopoietic stem cell transplantation for Gaucher disease.

Authors:  Usha R Somaraju; Krishna Tadepalli
Journal:  Cochrane Database Syst Rev       Date:  2017-10-18

Review 4.  Mandibular and dental manifestations of Gaucher disease.

Authors:  H R Saranjam; E Sidransky; W Z Levine; A Zimran; D Elstein
Journal:  Oral Dis       Date:  2012-01-18       Impact factor: 3.511

Review 5.  Alglucerase. A review of its therapeutic use in Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

6.  Type-3 Gaucher disease with bilateral necrosis of the neck of femur: a case report.

Authors:  Shobha Mohindroo
Journal:  Cases J       Date:  2009-12-22

7.  Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3.

Authors:  Maciej Machaczka; Cecilia Kämpe Björkvall; Joanna Wieremiejczyk; Martin Paucar Arce; Kristina Myhr-Eriksson; Monika Klimkowska; Hans Hägglund; Per Svenningsson
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-09-10       Impact factor: 4.291

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.